Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP4 | P12644 | 10/20 | 1.00 |
| ▸ | KDR | P35968 | 10/20 | 1.00 |
| ▸ | ACVR1 | Q04771 | 7/20 | 1.00 |
| ▸ | ACVR1B | P36896 | 6/20 | 1.00 |
| ▸ | TGFBR1 | P36897 | 6/20 | 1.00 |
| ▸ | PRKAB1 | Q9Y478 | 6/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 5/20 | 1.00 |
| ▸ | ACVRL1 | P37023 | 5/20 | 1.00 |
| ▸ | BMPR1A | P36894 | 4/20 | 1.00 |
| ▸ | TGFBR2 | P37173 | 4/20 | 1.00 |
| ▸ | BMPR2 | Q13873 | 3/20 | 0.67 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.64 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.64 |
| ▸ | ACVR2B | Q13705 | 1/20 | 0.64 |
| ▸ | FLT1 | P17948 | 1/20 | 0.63 |
| ▸ | FLT4 | P35916 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29395473 | 0.92 | ACVR1 (1.00) | BMP4KDRACVR1ACVR1BTGFBR1 | |
| SCHEMBL11953869 | 0.92 | ACVR1 (1.00) | BMP4KDRACVR1ACVR1BTGFBR1 | |
| SCHEMBL29360662 | 0.88 | ACVR1 (1.00) | BMP4KDRACVR1ACVR1BTGFBR1 | |
| SCHEMBL14671947 | 0.88 | ACVR1 (1.00) | BMP4KDRACVR1ACVR1BTGFBR1 | |
| SCHEMBL12779920 | 0.87 | BMP4 (0.82) | BMP4KDRACVR1ACVR1BTGFBR1 | |
| SCHEMBL11953449 | 0.87 | BMP4 (1.00) | BMP4KDRACVR1ACVR1BTGFBR1 | |
| SCHEMBL12844954 | 0.86 | BMP4 (0.80) | BMP4KDRACVR1ACVR1BTGFBR1 | |
| SCHEMBL2059665 | 0.85 | BMP4 (1.00) | BMP4KDRACVR1ACVR1BTGFBR1 | |
| SCHEMBL11953443 | 0.85 | BMP4 (1.00) | BMP4KDRACVR1ACVR1BTGFBR1 | |
| SCHEMBL11953445 | 0.85 | BMP4 (1.00) | BMP4KDRACVR1ACVR1BTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398118-A1 | METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE | KEROS THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230372390-A1 | METHODS OF TREATING LYMPHOPENIA | KEROS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20220401445-A1 | METHODS OF USING ALK2 INHIBITORS | KEROS THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11318103-B2 | Treating soft tissue via controlled drug release | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2022-05-03 | — | — | US | disclosed |
| US-20190142758-A1 | TREATING SOFT TISSUE VIA CONTROLLED DRUG RELEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-05-16 | — | — | US | disclosed |
| US-10179111-B2 | Treating soft tissue via controlled drug release | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2019-01-15 | — | — | US | disclosed |
| US-20170014349-A1 | TREATING SOFT TISSUE VIA CONTROLLED DRUG RELEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-01-19 | — | — | US | disclosed |
| US-20160263117-A1 | COMPOSITIONS AND METHODS FOR CARDIOVASCULAR DISEASE | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-09-15 | — | — | US | disclosed |
| WO-2015134770-A1 | TREATING SOFT TISSUE VIA CONTROLLED DRUG RELEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2015-09-11 | — | — | WO | disclosed |
| US-9045484-B2 | Inhibitors of the BMP signaling pathway | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| EP-2265603-B1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | GEN HOSPITAL CORP (US) | 2014-05-07 | — | — | EP | disclosed |
| US-20140038953-A1 | COMPOSITIONS AND METHODS FOR CARDIOVASCULAR DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140011805-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2014-01-09 | — | — | US | disclosed |
| US-8507501-B2 | Inhibitors of the BMP signaling pathway | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| WO-2012100229-A2 | COMPOSITIONS AND METHODS FOR CARDIOVASCULAR DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2012-07-26 | — | — | WO | disclosed |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2009114180-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE GENERAL HOSPITAL CORPORATION (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263117-A1 | COMPOSITIONS AND METHODS FOR CARDIOVASCULAR DISEASE | APOB, BMP1, LDLR | BMP4 8/4885KDR 251/4885ACVR1 18/4885 |
| US-20220401445-A1 | METHODS OF USING ALK2 INHIBITORS | ALK, ACVR2A, ACVR1 | BMP4 64/4885KDR 46/4885ACVR1 3/4885 |
| US-10179111-B2 | Treating soft tissue via controlled drug release | BMP2, BMP1, BMP6 | BMP4 6/4885KDR 203/4885ACVR1 16/4885 |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | BMP1, BMP2K, BMP2 | BMP4 4/4885KDR 260/4885ACVR1 9/4885 |
| US-20170014349-A1 | TREATING SOFT TISSUE VIA CONTROLLED DRUG RELEASE | BMP2, BMP1, BMP6 | BMP4 6/4885KDR 203/4885ACVR1 16/4885 |
| US-20230398118-A1 | METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE | BMPR2, BMP1, BMP2 | BMP4 7/4885KDR 138/4885ACVR1 13/4885 |
| US-11318103-B2 | Treating soft tissue via controlled drug release | BMP2, BMP1, BMP6 | BMP4 6/4885KDR 203/4885ACVR1 16/4885 |
| US-20190142758-A1 | TREATING SOFT TISSUE VIA CONTROLLED DRUG RELEASE | BMP2, BMP1, BMP6 | BMP4 6/4885KDR 203/4885ACVR1 16/4885 |
| US-20140011805-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | BMP1, BMP2K, BMP2 | BMP4 4/4885KDR 260/4885ACVR1 9/4885 |
| US-20140038953-A1 | COMPOSITIONS AND METHODS FOR CARDIOVASCULAR DISEASE | APOB, BMP1, LDLR | BMP4 8/4885KDR 251/4885ACVR1 18/4885 |
| US-20230372390-A1 | METHODS OF TREATING LYMPHOPENIA | HAMP, BMPR2, BMP2 | BMP4 17/4885KDR 1564/4885ACVR1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.